12. Post-Cardiac Arrest Syndrome

Quick Recap

Neurology System, Protocol 12/12 — completing the Neurology System.

1. Epidemiology & Definition

Sudden cardiac arrest (SCA) affects >3.8 million people worldwide annually; survival to hospital discharge remains poor at only 8-12%. US: >350,000 out-of-hospital (OHCA) + >290,000 in-hospital (IHCA) arrests annually.

Post-cardiac arrest syndrome = a complex pathophysiologic process comprising: (1) post-cardiac arrest BRAIN injury, (2) post-cardiac arrest MYOCARDIAL dysfunction, (3) systemic ISCHEMIA/REPERFUSION response — occurring on top of whatever unresolved process caused the arrest in the first place.

Roughly two-thirds of in-hospital deaths in comatose OHCA survivors result from hypoxic-ischemic brain injury, the majority in the context of withdrawal of life-sustaining treatment based on perceived poor neurologic prognosis — making accurate, appropriately-timed neuroprognostication (Section 8) one of the highest-stakes tasks in this entire protocol library.

2. Temporal Framework

This framework organizes management, intervention timing, and (critically) the earliest appropriate timing for neurologic prognostication.

3. Immediate Stabilization (ABCDE)

Airway/Breathing: most patients require tracheal intubation if not already performed during CPR, by skilled personnel; a supraglottic airway is a reasonable bridge if skilled intubators are not immediately available.

Oxygenation targets: avoid BOTH hypoxemia (worsens/precipitates ischemic brain injury — observational association with poor outcomes) AND hyperoxia (worsens brain injury via oxidant stress — animal models show worse neurologic injury with 100% O2 vs lower concentrations). Target SpO2 94-98%.

Ventilation: lung-protective strategy, Vt 6-8 mL/kg IBW (same principle as ARDS management, applied here regardless of whether ARDS is present). PaCO2 target: normal range 35-45 mmHg in patients without preexisting chronic hyper/hypocapnia — evidence on optimal PaCO2 is mixed; extreme hypocapnia AND extreme hypercapnia are both associated with poor outcomes; mild hypercapnia correlates with lower NSE (a brain injury biomarker) but clinical outcome benefit from deliberately targeting mild hypercapnia is unclear — default to normocapnia rather than deliberately over- or under-shooting.

Prophylactic antibiotics for aspiration risk: NOT routinely recommended — one RCT showed reduced early VAP with 48h prophylactic antibiotics, but a broader systematic review/meta-analysis (3 RCTs + 8 observational studies) found NO association with survival, neurologic recovery, ICU LOS, or pneumonia rate. Current evidence argues against routine prophylactic antibiotic use.

Hemodynamics:

• Cerebral autoregulation is frequently DYSREGULATED after cardiac arrest — the normal relationship between cerebral blood flow and MAP may be flattened or shifted, meaning a "one-size-fits-all" MAP target may not be appropriate for every patient (Neuroprotect trial explored MAP 65 vs 85 targets; NIRS-based individualized autoregulation monitoring is an emerging but not yet standard approach)
• ~50% of post-SCA patients may develop critical illness-related corticosteroid insufficiency (CIRCI); a subset also develop a SIRS-like picture mimicking sepsis (vasodilation, hypotension) — note sepsis can be BOTH a cause of arrest and a consequence (e.g., aspiration pneumonia), so work up SIRS/sepsis signs appropriately rather than assuming they are purely post-arrest inflammatory phenomena
• Corticosteroid use post-arrest remains genuinely unresolved: pooled analysis of 3 earlier trials showed favorable but NON-statistically-significant trends (shock reversal RR 1.42, survival to discharge RR 1.96, good neurologic recovery RR 1.45); the more recent, larger CORTICA trial (2022, n=100) found NO differences in hemodynamics, temperature, organ-failure-free days, or in-hospital/functional outcomes with stress-dose steroids vs placebo. Current evidence does NOT support routine low-dose corticosteroid use after cardiac arrest.

Checklist:

4. Temperature Management — The Evolving Evidence Base

Rationale for cooling: hypothermia reduces cerebral O2 consumption/metabolic rate (~6% per degree C reduced), may reduce ischemia-reperfusion injury, neuroinflammation, and free radical production. Risks: bradycardia, BP instability, dysrhythmias, reduced gut motility, coagulopathy, shivering, electrolyte/metabolic derangement.

Trial evolution (know this trajectory — practice has shifted significantly):

• HACA trial (2002): 33-34C vs normothermia post-VF arrest — favorable neurologic outcome 55% vs 39%, 6-month mortality 41% vs 55% (favoring hypothermia)
• Bernard et al. (2002): similar favorable hypothermia signal
• TTM1 trial (2013): 33C vs 36C — NO significant difference in mortality or neurologic outcome between the two temperature targets
• HYPERION trial (2019): 33C vs normothermia in NON-shockable initial rhythm OHCA — improved 90-day favorable neurologic survival (10.2% vs 5.7%) WITH hypothermia in this specific subgroup
• TTM2 trial (2021, largest to date, n=1900): 33C vs normothermia (<=37.5C) WITH early fever treatment — NO significant difference in 6-month mortality or neurologic outcome; HIGHER rates of hemodynamically significant arrhythmia in the hypothermia group

Current synthesis: aggressive fever PREVENTION/management appears roughly equivalent to induced hypothermia regardless of initial rhythm, without hypothermia's added harms — but genuine controversy remains, since HYPERION suggested a possible benefit specifically in non-shockable rhythms, and some patient subsets may still benefit from therapeutic hypothermia. All patients should undergo aggressive fever prevention/management for the first 72 hours after ROSC regardless of which temperature strategy is chosen — this is the one point of clear consensus.

If therapeutic TTM (hypothermia) is selected for a patient: target 32-36C for at least 24-48 hours, followed by CONTROLLED rewarming at 0.25C/hour (rapid rewarming risks rebound cerebral edema/ICP, analogous to the SRSE hypothermia rewarming caution in the Status Epilepticus protocol). Manage shivering pharmacologically (opioids, sedatives); avoid prolonged neuromuscular blockade as it interferes with neurologic exam — reserve as a last resort for refractory shivering only.

Continuous core temperature monitoring (bladder or esophageal probe) is essential regardless of strategy chosen.

5. Sedation Strategy

Use short-acting agents (propofol or dexmedetomidine) if sedation is needed — this is essential for enabling timely, accurate neurologic prognostication later (Section 8), since long-acting sedatives (or their active metabolites, especially with renal/hepatic dysfunction) can confound the exam for days.

6. Seizures

Occur in ~20-30% of comatose post-SCA patients — can be clinical (convulsive) or purely electrographic (nonconvulsive status epilepticus). Continuous EEG helps identify nonconvulsive status epilepticus, though no demonstrated outcome benefit over routine/intermittent EEG has been shown in this specific population — an honest evidence gap worth knowing. Antiepileptic drugs (levetiracetam, valproic acid, fosphenytoin, lacosamide) should be used to TREAT seizures when identified — there is NO evidence supporting PROPHYLACTIC AED use in post-arrest patients (consistent with the no-prophylaxis principle seen elsewhere in this Neurology system for Stroke/ICH, in contrast to TBI's evidence-supported time-limited prophylaxis).

Shivering can mimic or confound seizure activity both clinically and on EEG — a brief trial of short-acting paralytic can help differentiate the two when genuinely uncertain.

7. Post-Cardiac Arrest Status Epilepticus — Cross-Reference to Status Epilepticus Protocol

Postanoxic SE (per the Status Epilepticus protocol) is a special, more ominous category — especially with myoclonic jerking, it's one of the most consistent predictors of death/non-recovery, EXCEPT when accompanied by a preserved brainstem exam and reactive EEG. Postanoxic myoclonus/SE may transiently respond to valproate, clonazepam, or levetiracetam but is usually refractory overall; aggressive escalation should generally be withheld pending explicit prognosis discussion with family in this specific context — do not treat postanoxic SE identically to other SE etiologies without this framing.

8. Neuroprognostication — The Highest-Stakes Decision in This Protocol

Timing is critical and non-negotiable:

• Brain death cannot be declared until at least 24 hours after ROSC OR after rewarming to normothermia (whichever is later)
• In the absence of brain death, neurologic prognostication CANNOT be assessed until AT LEAST 72 hours after ROSC
• Must occur in the ABSENCE of hypothermia, severe metabolic derangement, sedation, or neuromuscular blockade — if sedatives/paralytics were used, wait AT LEAST 5 elimination half-lives of the longest-acting drug administered before relying on the exam, with even MORE time required in renal/hepatic dysfunction (which alters pharmacokinetics, especially for drugs with active metabolites)

Multimodal assessment (physical exam + biomarkers + functional testing/imaging), NOT reliance on any single test:

Predictors of POOR neurologic outcome (CPC 3-5 / severe disability-death), from systematic review/meta-analysis of >87 studies (both hypothermia-treated and untreated patients):

• Status myoclonus at 24-48 hours
• Bilateral absence of SSEP N20 wave
• Malignant EEG activity (suppressed background or burst suppression) at 24-72 hours
• Absence of pupillary AND corneal reflexes at 72 hours
• NSE (neuron-specific enolase) >60 mcg/L at 48 and/or 72 hours
• Diffuse anoxic brain injury on CT or MRI

Decision rule: in comatose patients with GCS motor score <=3 (M<=3) at >=72 hours post-ROSC, in the absence of confounders, poor neurologic outcome is HIGHLY LIKELY (0% false-positivity rate in the underlying meta-analysis) when at least TWO of the above predictors are present. This multimodal, dual-predictor threshold is specifically designed to minimize the risk of an inappropriately pessimistic prognosis leading to premature withdrawal of care in a patient who might actually recover.

Outcome measurement tools: Cerebral Performance Category (CPC) or modified Rankin Score (mRS).

Organ donation: patients diagnosed with brain death, or those with predicted poor neurologic recovery for whom family is pursuing withdrawal of life-sustaining treatment, should be considered for organ donation where appropriate — raise this proactively as part of end-of-life planning rather than as an afterthought.

9. Organ Support

Mechanical ventilation per Section 3 targets; temperature management per Section 4; hemodynamic support with individualized MAP targeting where feasible (cerebral autoregulation dysregulation, Section 3); standard ICU supportive care; treat the underlying arrest cause in parallel (coronary reperfusion per ACS protocol if cardiac etiology, per Section 3).

10. Consultation Matrix

11. Monitoring Framework

Continuous core temperature monitoring, continuous EEG (or serial routine EEG) for seizure/myoclonus surveillance, serial neuro exams timed appropriately relative to sedative clearance, NSE trending at 48/72h if available, SSEP testing per neurology, serial pupillary/corneal reflex assessment, hemodynamic monitoring with individualized MAP consideration.

12. Complications

Recurrent arrest, arrhythmia (esp. with hypothermia), hemodynamic instability, seizures/status epilepticus, aspiration pneumonia, multi-organ dysfunction from the ischemia-reperfusion syndrome, premature/inappropriate withdrawal of care from mistimed or single-modality prognostication. Prevention: appropriate oxygenation/ventilation targets, aggressive fever control, avoiding prophylactic antibiotics (no proven benefit), short-acting sedation to preserve exam reliability, adherence to the strict 72-hour+ multimodal prognostication timing. Rescue: standard ICU support; there is no rescue therapy for established severe hypoxic-ischemic brain injury beyond supportive care and time.

13. Escalation & De-escalation

Escalate: hemodynamic instability -> individualized MAP targeting, treat underlying cause; new seizures -> AEDs (not prophylactic); recurrent fever -> aggressive active cooling.

De-escalate: hemodynamically stable, temperature controlled, past the acute ischemia-reperfusion window (>72h) -> transition per neuroprognostication outcome to either escalating rehabilitation-focused care or goals-of-care/comfort-focused pathway.

14. ICU Discharge Criteria

Hemodynamically stable, underlying arrest cause addressed (e.g., revascularized if cardiac), temperature normalized and stable off active management, neuroprognostication completed with a clear multimodal assessment and family discussion, rehabilitation plan established for patients with favorable/uncertain prognosis, or comfort-focused transition plan for those with confirmed poor prognosis.

15. Documentation & Medicolegal Checklist

16. Key Guidelines

Nolan JP, Sandroni C, Böttiger BW, et al. European Resuscitation Council and European Society of Intensive Care Medicine guidelines 2021: post-resuscitation care. Intensive Care Med. 2021;47(4):369-421 — primary contemporary reference.

17. Landmark Trials

• HACA (2002) and Bernard et al. (2002): foundational hypothermia-favoring trials that established early TTM practice.
• TTM1 (2013): 33C vs 36C — no difference, shifted practice toward less aggressive cooling targets.
• HYPERION (2019): hypothermia benefit signal specifically in non-shockable initial rhythm.
• TTM2 (2021, largest/most recent): 33C vs normothermia-with-fever-control — no difference in outcomes, more arrhythmia with hypothermia — the trial most responsible for the current shift toward fever-avoidance-only strategies in many centers.
• CORTICA (2022): no benefit from stress-dose corticosteroids post-arrest.
• Sandroni C et al.: systematic review/meta-analysis (>87 studies) underlying the multimodal neuroprognostication predictor list and the 0% false-positivity dual-predictor threshold.

18. Controversies

Temperature management strategy (33C hypothermia vs normothermia-with-fever-avoidance) remains genuinely unresolved despite TTM2's null result — HYPERION's non-shockable-rhythm subgroup signal keeps this an active area, and reasonable clinicians/centers differ in practice. Individualized, autoregulation-guided MAP targeting (vs a fixed MAP goal) is promising (NIRS-based approaches) but not yet standard of care. Continuous vs routine/intermittent EEG monitoring lacks demonstrated outcome benefit despite widespread continuous EEG use in this population. Corticosteroid use remains not-recommended based on current best evidence (CORTICA) despite earlier suggestive (non-significant) trends in older pooled data.

19. References

1. Grotberg JC, Kraft BD. Post-Cardiac Arrest Management. Washington Manual of Critical Care, 4th ed, 2025 (Ch. 25).
2. Nolan JP, Sandroni C, Böttiger BW, et al. European Resuscitation Council and European Society of Intensive Care Medicine guidelines 2021: post-resuscitation care. Intensive Care Med. 2021;47(4):369-421.
3. Nielsen N, Wetterslev J, Cronberg T, et al. Targeted temperature management at 33°C versus 36°C after cardiac arrest (TTM1). N Engl J Med. 2013;369(23):2197-2206.
4. Dankiewicz J, Cronberg T, Lilja G, et al. Hypothermia versus normothermia after out-of-hospital cardiac arrest (TTM2). N Engl J Med. 2021;384(24):2283-2294.
5. Lascarrou JB, Merdji H, Le Gouge A, et al. Targeted temperature management for cardiac arrest with nonshockable rhythm (HYPERION). N Engl J Med. 2019;381(24):2327-2337.
6. Sandroni C, Cavallaro F, Callaway CW, et al. Predictors of poor neurological outcome in adult comatose survivors of cardiac arrest: systematic review and meta-analysis. Part 2. Resuscitation. 2013;84(10):1324-1338.
7. Neumar RW, Nolan JP, Adrie C, et al. Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication. Circulation. 2008;118:2452-2483.

See also: Status Epilepticus (Neurology System) for the postanoxic SE special case; Acute Coronary Syndrome (Cardiovascular System) for reperfusion management if the arrest was cardiac in origin.